Company Overview and News
DENVER, March 28, 2018 (GLOBE NEWSWIRE) -- Sundance Energy Australia Limited (ASX:SEA) (NASDAQ:SNDE) (“Sundance” or the “Company”), a U.S. onshore oil and gas exploration and production company focused in the Eagle Ford in South Texas is pleased to announce its proved reserves at 31 December 2017. Sundance’s year end reserves do not include the impact of the recently announced acquisition of approximately 21,900 acres in the Eagle Ford.
Pioneer Natural Resources Company (PXD - Free Report) has recently reported that it has agreed to divest around 10,200 net acres from its Eagle Ford Shale's western part to Sundance Energy, Inc., a subsidiary of Sundance Energy Australia Limited (SNDE - Free Report) .
Chicago, IL – January 23, 2017 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Sundance Energy Australia Ltd. (NASDAQ: (SNDE - Free Report) - Free Report ), Plains All American Pipeline L.P. (NYSE: (PAA - Free Report) - Free Report ), Western Refining Inc.
Known to be extremely volatile, the industry began the year by falling to $26-a-barrel -- the lowest since 2003. This set off a wave of bankruptcy filings, with dozens of small and high-cost U.S. producers asking for protection under Chapter 11.
Chicago, IL – January 19, 2017, 2016 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Archrock Partners, L.P. (NASDAQ: (APLP - Free Report) – Free Report ), Global Partners LP (NYSE: (GLP - Free Report) – Free Report ), Sundance Energy Australia Limited (NASDAQ:(SNDE - Free Report) – Free Report ) and Plains All American Pipeline, L.
The oil and gas industry isn’t out of the woods yet, but energy companies are likely to exhibit a radical change in their approach toward spending this year. After years of combating plunging prices with cutbacks, expenditure for the sector is projected to increase over 2017. Signs are already evident, with Tuesday witnessing the announcement of additional deals based around Permian plays.
Chicago, IL – January 18, 2017 - Stocks in this week’s article include Glaukos Corporation (NYSE: (GKOS - Free Report) – Free Report ), Apogee Enterprises Inc. (NASDAQ: (APOG - Free Report) – Free Report ), Braskem SA (NYSE: (BAK - Free Report) – Free Report ), Sundance Energy Australia Limited (NASDAQ: (SNDE - Free Report) – Free Report ) and Angang Steel Company Limited (OTCMKTS: (ANGGY - Free Report) – Free Report ).
For the first time in the last 10 weeks, U.S. oil rig count has declined. This was quite unexpected, especially in a time when crude has started regaining positive momentum. The news is as per the data provided by oilfield services player Baker Hughes Incorporated (BHI - Free Report) .
Noble Energy, Inc. (NBL - Free Report) entered into a definitive agreement to acquire Clayton Williams Energy, Inc. (CWEI - Free Report) in a bid to expand its footprint in Permian Basin – the U.S.’ most prolific oil-producing region. The transacted is anticipated to close in the second quarter of 2017.
Noble Energy, Inc. (NBL - Free Report) completed the acquisition of 7,200 net acres in the Southern Delaware Basin in Reeves County, TX. The acquisition price of $300 million was funded with available cash on hand.
2018-04-18 - Asif
History and Development of the Company The company's legal and commercial name is RedHill Biopharma Ltd. The company's company was incorporated on August 3, 2009, and was registered as a private company limited by shares under the laws of the State of Israel. The company's principal executive offices are located at 21 Ha’arba’a Street, Tel Aviv, Israel. In February 2011, the company completed its initial public offering in Israel, pursuant to which the company issued 14,302,300 Ordinary Shares, and 7,151,150 tradable Series 1 Warrants to purchase 7,151,150 Ordinary Shares for aggregate gross proceeds of approximately $14 million. On December 27, 2012, the company completed the listing of its ADSs on the NASDAQ Capital Market. The company's Ordinary Shares are traded on the Tel-Aviv Stock Exchange under the symbol “RDHL,” and its ADSs are traded on the NASDAQ Capital Market under the same symbol "RDHL". The company's capital expenditures for the years ended December 31, 2...
2018-04-16 - Asif
Overview SCYNEXIS, Inc. is a biotechnology company committed to positively impacting the lives of patients suffering from difficult-to-treat and often life-threatening infections by delivering innovative anti-infective therapies. SCYNEXIS is developing its lead product candidate, SCY-078, as the first representative of a novel oral and intravenous (IV) triterpenoid antifungal family in clinical development for the treatment of several serious fungal infections, including invasive candidiasis, invasive aspergillosis, refractory invasive fungal infections and vulvovaginal candidiasis (VVC). SCY-078 is a structurally distinct glucan synthase inhibitor that has been shown to be effective in vitro and in vivo against a broad range of human fungi pathogens such as Candida and Aspergillus species, including multidrug-resistant strains, as well as Pneumocystis species. Candida and Aspergillus species are the fungi responsible for approximately 85% of all invasive fungal infections in t...
2018-04-16 - Asif
Business History Enertopia Corp. was formed on November 24, 2004 under the laws of the State of Nevada and commenced operations on November 24, 2004. From inception until April 2010, the company were primarily engaged in the acquisition and exploration of natural resource properties. Beginning in April 2010, the company began its entry into the renewable energy sector by purchasing an interest in a solar thermal design and installation company. In late summer 2013, the company began its entry into medicinal marijuana business. During its 2014 fiscal year end its activities in the clean energy sector were discontinued. During fiscal 2015 its activities in the Medicinal Marijuana sector were discontinued. During fiscal 2016 its activities in the Women’s personal healthcare sector were discontinued. The Company is actively pursuing business opportunities in the resource sector, whereby the company signed a definitive agreement for a Lithium Brine Project in May 2016. In May ...
2018-04-15 - Asif
Overview The company's mission is to give people the power to build community and bring the world closer together. The company's top priority is to build useful and engaging products that enable people to connect and share with friends and family through mobile devices, personal computers, and other surfaces. The company also help people discover and learn about what is going on in the world around them, enable people to share their opinions, ideas, photos and videos, and other activities with audiences ranging from their closest friends to the public at large, and stay connected everywhere by accessing its products, including: Facebook enables people to connect, share, discover, and communicate with each other on mobile devices and personal computers. There are a number of different ways to engage with people on Facebook, the most important of which is News Feed which displays an algorithmically-ranked series of stories and advertisements individualized for each pers...
2018-04-12 - Asif
Business Overview Verastem is a biopharmaceutical company focused on developing and commercializing drugs to improve the survival and quality of life of cancer patients. The company's most advanced product candidates, duvelisib and defactinib, utilize a multi-faceted approach to treat cancers originating either in the blood or major organ systems. Verastem is currently evaluating these compounds in both preclinical and clinical studies as potential therapies for certain cancers, including leukemia, lymphoma, lung cancer, ovarian cancer, mesothelioma, and pancreatic cancer. The company believe that these compounds may be beneficial as therapeutics either as single agents or when used in combination with immuno-oncology agents or other current and emerging standard of care treatments in aggressive cancers that are poorly served by currently available therapies. Duvelisib targets the Phosphoinositide 3-kinase (PI3K) signaling pathway. The PI3K signaling pathway plays a centr...